dry eye disease

Diquafosol Tetrasodium is a P2Y2 receptor agonist that stimulates the secretion of mucins from ocular tissues Diquafosol tetrasodium (INS365) improves tear film stability and visual function, as a topical treatment of dry eye disease.

Tivanisiran (SYL1001) is a siRNA developed specifically to inhibit the expression of transient receptor potential vanilloid 1 (TRPV1) to explore its implications in dry eye disease research.

TOP1362 is a Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. TOP1362 strongly inhibited the kinase targets p38α, Syk, Src, and Lck, blocked the rise in p38α expression in hyperosmolar Chang cells, and potently reduced inflammatory cytokine release in cellular models of innate and adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-induced rise in inflammatory cell infiltration and ocular cytokine levels with efficacy comparable to that of dexamethasone.

R-932348 choline, a dual JAK/SYK inhibitor, is used potentially for treatment of dry eye disease.

JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2. The compound has been identified as having research potential for the treatment of dry eye disease (DED) [1].

Lifitegrast (SAR 1118) is a lymphocyte, function-associated antigen-1 antagonist.